Cell Line : NCC-STC-K140
Cellosaurus Index : CVCL_3055
Cellosaurus ID : NCC-STC-K140
CCLE Name
: NCCSTCK140_STOMACH
CTRP2 Name
: NCCSTCK140
Cancer Type : stomach
Dataset : All
Drug Response Information
Click to show/hide information cards below or download all drug response information.
Information cards below will change according to the dataset selected. The default dataset is “All”, which means information in the cards is based on the integration. If “All” is not selected, information cards will contain drug response information preprocessed for each dataset independently.
Experimental information
Experimental information from All dataset, including cell line name, drug name, and minimum and maximum dosages used in each experiment. Click on Dose-response to query more detail for each experiment.
| Cellosaurus ID | Drug Name | Original Dataset(s) | Min Dose | Max Dose | Dose-response |
|---|---|---|---|---|---|
| NCC-STC-K140 | 16-beta-bromoandrosterone | CTRP2 | 0.0011 | 37.0000 |
|
| NCC-STC-K140 | 1S,3R-RSL-3 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | A-804598 | CTRP2 | 0.0041 | 66.0000 |
|
| NCC-STC-K140 | AA-COCF3 | CTRP2 | 0.2600 | 33.0000 |
|
| NCC-STC-K140 | AC55649 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Afatinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | alisertib:navitoclax (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| NCC-STC-K140 | Alpelisib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | alvocidib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | AM-580 | CTRP2 | 0.0160 | 530.0000 |
|
| NCC-STC-K140 | ASN 05257430 | CTRP2 | 0.0011 | 37.0000 |
|
| NCC-STC-K140 | AT13387 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | AT7867 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | austocystin D | CTRP2 | 0.0011 | 37.0000 |
|
| NCC-STC-K140 | avicin D | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | avrainvillamide | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Axitinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | azacitidine | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | AZD-7545 | CTRP2 | 0.0023 | 0.2900 |
|
| NCC-STC-K140 | AZD1480 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | AZD8055 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | barasertib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Belinostat | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BI-2536 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | BIBR-1532 | CTRP2 | 0.0081 | 270.0000 |
|
| NCC-STC-K140 | bleomycin A2 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Bortezomib | CTRP2 | 0.0000 | 0.1300 |
|
| NCC-STC-K140 | Bosutinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-A02303741 | CTRP2 | 0.0017 | 55.0000 |
|
| NCC-STC-K140 | BRD-A71883111 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | BRD-A86708339 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K02492147 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K07442505 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K11533227 | CTRP2 | 0.0020 | 0.2600 |
|
| NCC-STC-K140 | BRD-K14844214 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K16147474 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K17060750 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K19103580 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K41597374 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K42260513 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K48477130 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K50799972 | CTRP2 | 0.0020 | 17.0000 |
|
| NCC-STC-K140 | BRD-K52037352 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K61166597 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K63431240 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K64610608 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | BRD-K66532283 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K71781559 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K71935468 | CTRP2 | 0.0025 | 83.0000 |
|
| NCC-STC-K140 | BRD-K85133207 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-K90370028 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | BRD-K97651142 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD-M00053801 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD1812 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | BRD1835 | CTRP2 | 0.0041 | 130.0000 |
|
| NCC-STC-K140 | BRD8899 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | BRD9876 | CTRP2 | 0.0041 | 130.0000 |
|
| NCC-STC-K140 | canertinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | carboplatin:etoposide (40:17 mol-mol) | CTRP2 | 0.0014 | 47.0000 |
|
| NCC-STC-K140 | CD-437 | CTRP2 | 0.0011 | 18.0000 |
|
| NCC-STC-K140 | Cediranib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | ceranib-2 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | cerulenin | CTRP2 | 0.0045 | 150.0000 |
|
| NCC-STC-K140 | Ch-55 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | CHEMBL1222381 | CTRP2 | 0.0081 | 270.0000 |
|
| NCC-STC-K140 | CHM-1 | CTRP2 | 0.0005 | 16.0000 |
|
| NCC-STC-K140 | ciclosporin | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | clofarabine | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | CR-1-31B | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Crizotinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | crizotinib:PLX-4032 (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| NCC-STC-K140 | cucurbitacin I | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Dactolisib | CTRP2 | 0.0005 | 17.0000 |
|
| NCC-STC-K140 | Daporinad | CTRP2 | 0.0001 | 0.0078 |
|
| NCC-STC-K140 | Dasatinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | DBeQ | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Decitabine | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Dinaciclib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Docetaxel | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | docetaxel:tanespimycin (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| NCC-STC-K140 | Doxorubicin | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | doxorubicin:navitoclax (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| NCC-STC-K140 | elocalcitol | CTRP2 | 0.0020 | 0.2600 |
|
| NCC-STC-K140 | epigallocatechin-3-monogallate | CTRP2 | 0.0090 | 1.2000 |
|
| NCC-STC-K140 | erastin | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Erlotinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | erlotinib:PLX-4032 (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| NCC-STC-K140 | fluorouracil | CTRP2 | 0.0041 | 130.0000 |
|
| NCC-STC-K140 | fluvastatin | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Gefitinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Gemcitabine | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | GMX-1778 | CTRP2 | 0.0000 | 0.3000 |
|
| NCC-STC-K140 | gossypol | CTRP2 | 0.0011 | 37.0000 |
|
| NCC-STC-K140 | GSK-3 inhibitor IX | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | GSK1059615 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | GSK2636771 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | GSK461364 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | GW843682X | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | HLI 373 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | I-BET-762 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Ibrutinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | indisulam | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | isoevodiamine | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | isonicotinohydroxamic acid | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | ISOX:bortezomib (250:1 mol-mol) | CTRP2 | 0.0005 | 17.0000 |
|
| NCC-STC-K140 | istradefylline | CTRP2 | 0.2600 | 33.0000 |
|
| NCC-STC-K140 | itraconazole | CTRP2 | 0.0005 | 17.0000 |
|
| NCC-STC-K140 | JQ-1:MK-0752 (1:1 mol-mol) | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | JW-74 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | KH-CB19 | CTRP2 | 0.0005 | 17.0000 |
|
| NCC-STC-K140 | Ki8751 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Ko-143 | CTRP2 | 0.0041 | 130.0000 |
|
| NCC-STC-K140 | KU 0060648 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | KX2-391 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Lapatinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | LBH-589 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | leptomycin B | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Linifanib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Linsitinib | CTRP2 | 0.0010 | 0.1300 |
|
| NCC-STC-K140 | lovastatin acid | CTRP2 | 0.0041 | 130.0000 |
|
| NCC-STC-K140 | LY-2183240 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Masitinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Methotrexate | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | MG-132 | CTRP2 | 0.0006 | 20.0000 |
|
| NCC-STC-K140 | MK-0752 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | MK-1775 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | MK-2206 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | ML030 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | ML162 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | ML203 | CTRP2 | 0.0011 | 37.0000 |
|
| NCC-STC-K140 | ML210 | CTRP2 | 0.2600 | 33.0000 |
|
| NCC-STC-K140 | ML311 | CTRP2 | 0.0010 | 66.0000 |
|
| NCC-STC-K140 | MLN2238 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | MLN2480 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | momelotinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | N9-isopropylolomoucine | CTRP2 | 3.1000 | 400.0000 |
|
| NCC-STC-K140 | nakiterpiosin | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | narciclasine | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Navitoclax | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | navitoclax:gemcitabine (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | neratinib | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | NSC23766 | CTRP2 | 0.0160 | 530.0000 |
|
| NCC-STC-K140 | NSC30930 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | NSC48300 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | NSC632839 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Nutlin-3a | CTRP2 | 0.0045 | 150.0000 |
|
| NCC-STC-K140 | NVP-TAE684 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Olaparib | CTRP2 | 0.0045 | 150.0000 |
|
| NCC-STC-K140 | oligomycin A | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | omacetaxine mepesuccinate | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | OSI-027 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | ouabain | CTRP2 | 0.0081 | 270.0000 |
|
| NCC-STC-K140 | Oxaliplatin | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Paclitaxel | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | palmostatin B | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | parbendazole | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Parthenolide | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Pazopanib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | PD318088 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | PF-3758309 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | PI-103 | CTRP2 | 0.0011 | 37.0000 |
|
| NCC-STC-K140 | Pictilisib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | pifithrin-alpha | CTRP2 | 0.0071 | 230.0000 |
|
| NCC-STC-K140 | pifithrin-mu | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | pitstop2 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | PL-DI | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Platin | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | PLX-4720 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | PRL-3 Inhibitor I | CTRP2 | 0.0041 | 130.0000 |
|
| NCC-STC-K140 | procarbazine | CTRP2 | 0.0020 | 0.2600 |
|
| NCC-STC-K140 | R428 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Rapamycin | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | SB-225002 | CTRP2 | 0.0011 | 37.0000 |
|
| NCC-STC-K140 | SB-431542 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | SB-743921 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Selumetinib | CTRP2 | 0.0081 | 270.0000 |
|
| NCC-STC-K140 | selumetinib:BRD-A02303741 (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| NCC-STC-K140 | selumetinib:decitabine (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| NCC-STC-K140 | selumetinib:JQ-1 (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| NCC-STC-K140 | selumetinib:MK-2206 (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| NCC-STC-K140 | selumetinib:navitoclax (8:1 mol-mol) | CTRP2 | 0.0046 | 75.0000 |
|
| NCC-STC-K140 | selumetinib:piperlongumine (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| NCC-STC-K140 | selumetinib:PLX-4032 (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| NCC-STC-K140 | selumetinib:tretinoin (2:1 mol-mol) | CTRP2 | 0.0061 | 200.0000 |
|
| NCC-STC-K140 | selumetinib:UNC0638 (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| NCC-STC-K140 | selumetinib:vorinostat (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| NCC-STC-K140 | Sepantronium bromide | CTRP2 | 0.0080 | 1.0000 |
|
| NCC-STC-K140 | Serdemetan | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | SGX-523 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | sildenafil | CTRP2 | 0.0160 | 530.0000 |
|
| NCC-STC-K140 | silmitasertib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | sirolimus:bortezomib (250:1 mol-mol) | CTRP2 | 0.0005 | 17.0000 |
|
| NCC-STC-K140 | SJ-172550 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | SMER-3 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | SNX-2112 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | SNX-2112:bortezomib (250:1 mol-mol) | CTRP2 | 0.0005 | 17.0000 |
|
| NCC-STC-K140 | spautin-1 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | SR-II-138A | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | SU11274 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | tacedinaline | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | tacrolimus | CTRP2 | 0.0023 | 74.0000 |
|
| NCC-STC-K140 | tamatinib | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Tamoxifen | CTRP2 | 0.0030 | 100.0000 |
|
| NCC-STC-K140 | Tanespimycin | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | tanespimycin:gemcitabine (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | Telomerase Inhibitor IX | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | tipifarnib-P1 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | tivantinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | tosedostat | CTRP2 | 0.0081 | 270.0000 |
|
| NCC-STC-K140 | TPCA-1 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Trametinib | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Tretinoin | CTRP2 | 0.0041 | 130.0000 |
|
| NCC-STC-K140 | tretinoin:navitoclax (4:1 mol-mol) | CTRP2 | 0.0051 | 83.0000 |
|
| NCC-STC-K140 | triptolide | CTRP2 | 0.0000 | 0.3000 |
|
| NCC-STC-K140 | UNC0321 | CTRP2 | 0.0020 | 33.0000 |
|
| NCC-STC-K140 | VAF-347 | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | Vincristine | CTRP2 | 1.0000 | 130.0000 |
|
| NCC-STC-K140 | Vorinostat | CTRP2 | 0.0010 | 0.1300 |
|
| NCC-STC-K140 | vorinostat:carboplatin (1:1 mol-mol) | CTRP2 | 0.0020 | 66.0000 |
|
| NCC-STC-K140 | YK-4-279 | CTRP2 | 0.0010 | 33.0000 |
|
| NCC-STC-K140 | zebularine | CTRP2 | 4.6000 | 590.0000 |
|
| NCC-STC-K140 | ZSTK474 | CTRP2 | 0.0020 | 66.0000 |
|
IC50
IC50 indicates how much drug dosage is needed to inhibit the cells by 50%, in vitro, compared to the control well.
Drugs with highest and lowest IC50
Drugs with highest and lowest IC50
IC90
IC90 indicates how much drug dosage is needed to inhibit the cells by 90%, in vitro, compared to the control well.
Drugs with highest and lowest IC90
Drugs with highest and lowest IC90
AUC
AUC represents the area under a dose-response curve, where 0% indicates no activity and 100% indicates that a drug completely inhibits the cells across testing dosages.
Drugs with highest and lowest AUC
Drugs with highest and lowest AUC